Payment overview · 2025
General Payments
$147.24
2 reported records · 1 companies
Healthcare provider profile · identity verified
Dylan Dinesh, M.D.
Allopathic & Osteopathic Physicians|Hospitalist · SAINT PETERSBURG, FL · NPI 1962996231
Verified facts
What the public records show
CMS Open Payments records show Dylan Dinesh, M.D. received $147.24 in general payments during 2025 across 2 reported records.
Boston Scientific Corporation accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $147.24 | 100.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $147.24 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $147.24 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 297 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 297 | 32 |
| Amlodipine Besylate | Amlodipine Besylate | 179 | 61 |
| Eliquis | Apixaban | 153 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 45 |
| Doxycycline Hyclate | Doxycycline Hyclate | 148 | 74 |
| Alendronate Sodium | Alendronate Sodium | 146 | 15 |
| Gabapentin | Gabapentin | 134 | 27 |
| Famotidine | Famotidine | 131 | 24 |
| Simvastatin | Simvastatin | 125 | 14 |
| Lisinopril | Lisinopril | 124 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 118 | 58 |
| Mirtazapine | Mirtazapine | 116 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 33 |
| Divalproex Sodium | Divalproex Sodium | 114 | 12 |
| Furosemide | Furosemide | 112 | 45 |
| Omeprazole | Omeprazole | 103 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 95 | 82 |
| Metformin Hcl | Metformin Hcl | 92 | 18 |
| Levetiracetam | Levetiracetam | 90 | 17 |
| Montelukast Sodium | Montelukast Sodium | 90 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 81 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 81 | suppressed |
| Carvedilol | Carvedilol | 77 | 31 |
| Losartan Potassium | Losartan Potassium | 77 | 26 |
| Donepezil Hcl | Donepezil Hcl | 75 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 69 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 68 | suppressed |
| Prednisone | Prednisone | 67 | 49 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 65 | 57 |
| Ketoconazole | Ketoconazole | 65 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 63 | 34 |
| Potassium Chloride | Potassium Chloride | 63 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 61 | 53 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 53 | suppressed |
| Azithromycin | Azithromycin | 52 | 34 |
| Cephalexin | Cephalexin | 52 | 48 |
| Midodrine Hcl | Midodrine Hcl | 52 | 26 |
| Lactulose | Lactulose | 51 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 51 | suppressed |
| Nifedipine Er | Nifedipine | 47 | 28 |
| Pregabalin | Pregabalin | 47 | suppressed |
| Spironolactone | Spironolactone | 42 | 19 |
| Buspirone Hcl | Buspirone Hcl | 41 | suppressed |
| Metronidazole | Metronidazole | 40 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 27 |
| Lamotrigine | Lamotrigine | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 38 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 37 | suppressed |
| Enulose | Lactulose | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 26 |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 35 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 35 | 35 |
| Topiramate | Topiramate | 35 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 34 | 25 |
| Baclofen | Baclofen | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 34 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Alprazolam | Alprazolam | 31 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 13 |
| Jardiance | Empagliflozin | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | 14 |
| Cefuroxime | Cefuroxime Axetil | 26 | 24 |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Bumetanide | Bumetanide | 25 | 15 |
| Finasteride | Finasteride | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | 21 |
| Latanoprost | Latanoprost | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 23 |
| Mupirocin | Mupirocin | 23 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 23 | suppressed |
| Ertapenem | Ertapenem Sodium | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 18 |
| Ozempic | Semaglutide | 21 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 16 |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Lumigan | Bimatoprost | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 18 |
| Cefazolin Sodium | Cefazolin Sodium | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 18 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Cefdinir | Cefdinir | 17 | 15 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Nystatin | Nystatin | 17 | 15 |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | 13 |
| Sucralfate | Sucralfate | 16 | 12 |
| Acyclovir | Acyclovir | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 14 |
| Ramelteon | Ramelteon | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Budesonide Ec | Budesonide | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Entacapone | Entacapone | 13 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Daptomycin | Daptomycin | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $147.24 · 2 records | Boston Scientific Corporation | WaveWriter Alpha Prime 16 | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error